Primary Biliary Cirrhosis – Pipeline Review, H1 2019

Global Markets Direct’s, ‘Primary Biliary Cirrhosis – Pipeline Review, H1 2019’, provides an overview of the Primary Biliary Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis

– The report reviews pipeline therapeutics for Primary Biliary Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Primary Biliary Cirrhosis therapeutics and enlists all their major and minor projects

– The report assesses Primary Biliary Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Primary Biliary Cirrhosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Albireo Pharma Inc

Allergan Plc

Arena Pharmaceuticals Inc

Biocad

Cadila Healthcare Ltd

CymaBay Therapeutics Inc

Dr. Falk Pharma GmbH

Eli Lilly and Co

Enanta Pharmaceuticals Inc

Genfit SA

GenKyoTex SA

Gilead Sciences Inc

Kowa Co Ltd

NGM Biopharmaceuticals Inc

Novartis AG

Tiziana Life Sciences Plc

Virobay Inc

Table of Contents

Table of Contents

Table of Contents

Introduction

Primary Biliary Cirrhosis - Overview

Primary Biliary Cirrhosis - Therapeutics Development

Primary Biliary Cirrhosis - Therapeutics Assessment

Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development

Primary Biliary Cirrhosis - Drug Profiles

Primary Biliary Cirrhosis - Dormant Projects

Primary Biliary Cirrhosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Primary Biliary Cirrhosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Primary Biliary Cirrhosis – Pipeline by Albireo Pharma Inc, H1 2019

Primary Biliary Cirrhosis – Pipeline by Allergan Plc, H1 2019

Primary Biliary Cirrhosis – Pipeline by Arena Pharmaceuticals Inc, H1 2019

Primary Biliary Cirrhosis – Pipeline by Biocad, H1 2019

Primary Biliary Cirrhosis – Pipeline by Cadila Healthcare Ltd, H1 2019

Primary Biliary Cirrhosis – Pipeline by CymaBay Therapeutics Inc, H1 2019

Primary Biliary Cirrhosis – Pipeline by Dr. Falk Pharma GmbH, H1 2019

Primary Biliary Cirrhosis – Pipeline by Eli Lilly and Co, H1 2019

Primary Biliary Cirrhosis – Pipeline by Enanta Pharmaceuticals Inc, H1 2019

Primary Biliary Cirrhosis – Pipeline by Genfit SA, H1 2019

Primary Biliary Cirrhosis – Pipeline by GenKyoTex SA, H1 2019

Primary Biliary Cirrhosis – Pipeline by Gilead Sciences Inc, H1 2019

Primary Biliary Cirrhosis – Pipeline by Kowa Co Ltd, H1 2019

Primary Biliary Cirrhosis – Pipeline by NGM Biopharmaceuticals Inc, H1 2019

Primary Biliary Cirrhosis – Pipeline by Novartis AG, H1 2019

Primary Biliary Cirrhosis – Pipeline by Tiziana Life Sciences Plc, H1 2019

Primary Biliary Cirrhosis – Pipeline by Virobay Inc, H1 2019

Primary Biliary Cirrhosis – Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development for Primary Biliary Cirrhosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports